Blog

Category: News

Blue hued illustration of a DNA strand (double helix)

GID BIO reaches halfway enrollment in cell therapy trial

GID BIO reaches halfway enrollment in randomized double-blinded pivotal Phase III cell therapy trial
FDA-compliant trial addresses treatment gap for regenerative medicine to potentially treat knee osteoarthritis…

Dr. Manish Gupta joins the GIDOA-3 team

Dr. Manish Gupta, an orthopaedic surgeon with a sports medicine focus enters as GID BIO’s newest principal investigator in a pivotal trial of the GID SVF-2…

Two new employees join GID BIO team

GID BIO welcomes two new employees to the team as the newest of eight trial sites begin gearing up to enroll patients to participate in…

AdventHealth Orlando joins as newest trial site in pivotal trial

Tariq Awan, DO, a double-certified family and sports medicine physician with a special focus in sports medicine enters as GID BIO’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment…

UC Davis joins as trial site in pivotal trial

Charles De Mesa, DO, MPH, a Northern California practicing specialist in anesthesiology and pain medicine, physical medicine and rehabilitation and musculoskeletal pain medicine is GID Bio’s newest principal investigator in a pivotal trial…

OrthoCarolina joins as trial site in pivotal trial

OrthoCarolina, GID BIO’s newest trial site, is led by Dr. Claude T. Moorman III as principal investigator. Dr. Moorman is a sports medicine surgeon at OrthoCarolina’s Sports Medicine Center; the president of Atrium Health’s Musculoskeletal Institute; and Chair of Atrium Health’s Department of Orthopaedic Surgery…

Late-stage biotech GID BIO wins funding

LOUISVILLE, Colo. and PITTSBURGH, Aug. 18, 2020 — Following FDA clearance of an expanded access protocol to treat a small group of COVID-19 patients using the GID BIO technology platform, The Richard King Mellon Foundation has awarded $250,000 to GID BIO to conduct the study for patients with severe respiratory distress due to COVID-19…

error: Content is protected !!
Skip to content